Branded specialty drugs will drive all growth in 2018, while
traditional growth declines
• The past decade has seen a sustained shift in the focus of new medicines towards specialty pharmaceuticals.
These are defined as those medicines treating chronic, complex or rare conditions, among other criteria.
• Specialty share of global spending has risen from 19% in 2007 to 32% in 2017. For the tenth consecutive year,
specialty medicine growth exceeded traditional medicines in developed markets. In the ten developed markets,
specialty represented 39% of spending in 2017, totaling $297 billion.
• Specialty share in developed markets will continue to rise, albeit more slowly than the last few years, and surpass half of medicine spending in 2022 in the United States and in four out of the five key European countries:
France, Germany, United Kingdom and Spain.
BRANd SpENdINg gRoWTh of SpECIALTY ANd
TRAdITIoNAL dRUgS 2013-2022 IN dEvELopEd MARkETS